4.
|
Wie passt der Zukauf zu unserer Strategie?
|
Durch die Akquisition verbinden wir zwei Organisationen mit einer Pionier-Kultur der translationalen Wissenschaft und einer gemeinsamen Vision
für die Zukunft der Krebsimmuntherapie. Die Übernahme schafft langfristigen Wert für die Stakeholder von BioNTech (und Neon) durch die Kombination von Ressourcen, IT Systemen und Pipelines. Dies wird es ermöglichen, innovative
Immuntherapien für Krebspatienten auf der ganzen Welt zu entwickeln.
5.
|
Wie funktioniert die Übernahme, tauschen wir nur Neon-Aktien gegen BNTX-Aktien?
|
Ja, zu einem festgelegten Umtauschkurs von 0.0063 BNTX ADS zu einer Neon-Aktie.
6.
|
Wird Neon eine BNT Tochter werden?
|
Ja, Neon wird eine 100-prozentige Tochter der BioNTech SE werden.
Important Additional Information and Where to Find It
In
connection with the proposed merger, BioNTech will file with the Securities and Exchange Commission (the SEC) a Registration Statement on Form F-4 containing a proxy statement of Neon and a
prospectus of BioNTech, and each of Neon and BioNTech may file with the SEC other documents regarding the proposed merger. The definitive proxy statement will be mailed to stockholders of Neon. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE
REGISTRATION STATEMENT ON FORM F-4 AND THE PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH
THE PROPOSED MERGER, WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT BIONTECH, Neon AND THE PROPOSED MERGER.
Investors
and security holders may obtain copies of these documents free of charge through the website maintained by the SEC at www.sec.gov or from BioNTech at its website, https://biontech.de, or from Neon at its website, https://Neon.com. Documents filed
with the SEC by BioNTech will be available free of charge by accessing BioNTechs website under the heading Investors & Media, or, alternatively, by directing a request by telephone or mail to BioNTech at An der Goldgrube 12, 55131
Mainz, Germany, and documents filed with the SEC by Neon will be available free of charge by accessing Neons website at https://neontherapeutics.com under the heading Investor Resources or, alternatively, by directing a request by telephone or
mail to Neon at 40 Erie Street, Suite 110, Cambridge, MA 02139.
No Offer or Solicitation
This Q&A does not constitute an offer to sell or the solicitation of an offer to buy any securities nor a solicitation of any vote or approval with respect
to the proposed transaction or otherwise. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended, and otherwise in accordance with applicable
law.
Participants in Solicitation
BioNTech and Neon
and certain of their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Neon in respect of the proposed merger under the
rules of the SEC. Information about Neons directors and executive officers is available in Neons definitive proxy statement dated April 26, 2019 for its 2019 Annual Meeting of Stockholders and certain of its Current Reports on Form 8-K. Information about BioNTechs directors and executive officers is available in BioNTechs Registration Statement on Form F-1 filed with the SEC on
September 9, 2019, as amended. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy
statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or
investment decisions. You may obtain free copies of these documents from Neon or BioNTech using the sources indicated above.